Chronic GVHD: Intersecting Aspects in Systemic and Ocular Disease

摘要： 慢性眼部移植物抗宿主病(OGVHD)已被认为是同种异体角膜移植术后的重要并发症 造血干细胞移植(HSCT)是导致长期发病率和死亡率的主要原因 同种异体造血干细胞移植后。拟议的题为“慢性GVHD：系统性GVHD的交叉方面”的会议 和眼部疾病“将解决干眼和眼表疾病领域固有的困难。 由于慢性眼部GVHD-传播信息和开发新管理的困难 在快速变化的学科(眼部移植物抗宿主病的科学和临床治疗)中的战略 来自多个不同的人才库(眼科、血液学、临床实习生和研究人员 肿瘤学和免疫学)。这次会议致力于眼科医生和 在慢性移植物抗宿主病和干眼/眼表面疾病领域工作的血液学家/肿瘤学家。通过 汇集了来自不同学科的临床医生和科学家，包括国家公认的专家，这 会议将降低沟通障碍，促进跨学科研究和教育 促进改善慢性眼部移植物抗宿主病患者的管理。 我们于2016年10月22日在伊利诺伊大学举行了第二次慢性GVHD会议 芝加哥大学医学院(COM)学习中心。我们建议模拟未来的会议(2017-2022) 关于2016年会议的成功形式。这项拨款申请的总体目标是申请 支持下一个五年期年度会议的各个方面，以实现三项目标。刺激 临床和翻译跨学科合作和新的研究路线，会议将带来 联合全国公认的专家(血液学家/肿瘤学家和眼科医生)传播新的 慢性全身和眼部移植物抗宿主病领域的研究结果(目标1)。刺激机构间和 在研究、临床实践和教育方面的跨学科机会，会议将汇集五个 骨髓移植计划和芝加哥地区的六个眼科部门讨论 HSCT和慢性GVHD管理方法的差异以及 临床和研究合作(目标2)。加强初级和高级科学家之间的合作 在血液/肿瘤和眼科领域，将颁发20个旅游奖项，以增加 致力于研究、职业发展和早期基础科学的临床医生的参与 眼表疾病和移植物抗宿主病领域的研究人员(目标3)。将优先考虑女性， 少数族裔和残疾人。慢性GVHD会议计划于#年举行 符合继续医学评审委员会的基本领域和政策 教育(ACCME)，由伊利诺伊大学芝加哥分校(UIC)赞助。的范围和格式 这次会议是独一无二的，与小型指导课程或关于慢性疾病的共识会议有很大不同 近3年内行眼部GVHD。

Abstract: Chronic ocular GVHD (oGVHD) has been recognized as an important complication after allogeneic hematopoietic stem cell transplantation (HSCT) and is the leading cause of long-term morbidity and mortality following allogeneic HSCT. The proposed meeting entitled “Chronic GVHD: Intersecting aspects in systemic and ocular disease” will address a difficulty that is intrinsic in the area of dry eye and ocular surface disease due to chronic ocular GVHD - the difficulty in disseminating information and developing new management strategies in a fast-changing discipline (science and clinical treatment of ocular GVHD) where the stakeholders come from multiple disparate pools (clinician, clinical trainees and researchers in ophthalmology, hematology, oncology and immunology). This meeting is devoted to the intersection between ophthalmologist and hematologists/oncologists working in the areas of chronic GVHD and dry eye/ocular surface disease. By bringing together clinicians and scientists from different disciplines, including nationally recognized experts, this meeting will lower the communication barrier and promote interdisciplinary research and education and facilitate improvements in the management of patients with chronic ocular GVHD. We conducted the second Chronic GVHD Meeting on October 22, 2016 at the University of Illinois at Chicago (UIC) College of Medicine (COM) learning center. We propose to model future meetings (2017-2022) on the successful format of the 2016 meeting. The overall objective of this grant application is to request support for aspects of the annual meeting for the next 5-year period for achieving three aims. To stimulate clinical and translational interdisciplinary collaborations and new lines of research, the meeting will bring together nationally recognized experts (hematologist/oncologists and ophthalmologists) for disseminating new findings in the area of chronic systemic and ocular GVHD (Aim 1). To stimulate inter-institutional and interdisciplinary opportunities in research, clinical practice and education, the meeting will bring together five bone marrow transplant programs and six ophthalmology departments in the Chicago area to discuss differences in their approach to HSCT and chronic GVHD management and impediments/opportunities in clinical and research collaborations (Aim 2). To increase collaboration amongst junior and senior scientists in the fields of hematology/oncology and ophthalmology, 20 travel awards will be made to increase the participation of clinicians who are pursuing research career development and early stage basic science researchers in the areas of ocular surface disease and GVHD (Aim 3). Preference will be given to women, racial/ethnic minorities and persons with disabilities. The Chronic GVHD meeting has been planned in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) under the sponsorship of University of Illinois at Chicago (UIC). The scope and format of the meeting is unique and very different from the small instruction courses or consensus meetings on chronic ocular GVHD held in the past 3 years.